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Abstract. The aim of this study was to examine hemisphere asymmetry of response to pharmacologic treatment in an
Alzheimer’s disease mouse model using cilostazol as a chemical stimulus. Eight-month-old mice were assigned to vehicle
or cilostazol treatment for three months and hemispheres were analyzed using quantitative proteomics. Bioinformatics
interpretation showed that following treatment, aggregation of blood platelets significantly decreased in the right hemisphere
whereas neurodegeneration significantly decreased and synaptic transmission increased in the left hemisphere only. Our study
provides novel evidence on cerebral laterality of pharmacologic activity, with important implications in deciphering regional
pharmacodynamic effects of existing drugs thus uncovering novel hemisphere-specific therapeutic targets.
Keywords: Alzheimer’s disease, cilostazol, hemisphere asymmetry, mass spectrometry pharmacology, pharmacodynamics,
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INTRODUCTION
Structural asymmetry in the human brain was first
described by Broca in the 19th century [1]. Brain
asymmetries have also been described in other mam-
mals, including mice [2]. The asymmetry between
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cerebral hemispheres encompasses functional and
neurochemical aspects [3]. Data from gene expres-
sion studies in humans demonstrated lateralization of
gene transcription involved in synaptic transmission
and neuronal electrophysiology [4].
Cerebral laterality has been implicated in the
pathophysiology of Alzheimer’s disease [5]. How-
ever, whether therapeutic agents used for Alzheimer’s
disease exert hemisphere-specific pharmacologic
effects has yet to be elucidated.
Pharmacoproteomics, as a subdiscipline of
proteomics, examines how a pharmacologic agent
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perturbs a system of proteins that map to canoni-
cal or novel biological pathways. Such a discourse
provides a more unbiased and holistic approach to
understanding pharmacologic on-target or off-target
effects at the protein level [6–9].
We have shown that treatment with cilostazol, a
cyclic nucleotide phosphodiesterase III inhibitor, pre-
vented cognitive decline as a result of amyloid-
(A) deposition in the brain of Tg-SwDI mice [10].
Our hypothesis was that pharmacologic treatment of
Alzheimer’s disease exerts hemisphere asymmetry.
MATERIALS AND METHODS
Transgenic mouse model
To ensure reproducibility of the pharmacologic
treatment and subsequent proteomic analysis the
experiment was performed in duplicate. For experi-
ments A and B, male, eight-month-old, homozygous
Tg-SwDI mice (n = 6 per experiment, n = 12 in total)
on a pure C57BL/6 background were obtained from
Jackson Laboratories. These mice express low levels
of human Swedish/Dutch/Iowa mutant APP in neu-
rons under the control of the mouse Thy1.2 promoter.
Mice were randomly assigned to two groups and fed
with pelleted chow containing 0.3% cilostazol (n = 3
per experiment, n = 6 in total) or standard pelleted
chow only (n = 3 per experiment, n = 6 in total) for 3
months. Cilostazol was supplied by Otsuka Pharma-
ceutical Co. Ltd.
A previous study reported that in rats treated with
0.1% cilostazol, the plasma cilostazol concentration
was approximately 1M [11]. Based on the in vitro
IC50 value, this concentration is estimated to suf-
ficiently inhibit phosphodiesterase III activity [12].
Additionally, studies have shown that treatment with
0.1-0.3% cilostazol in rats positively affected vascu-
lar function [12, 13]. Based on this evidence, a 0.3%
cilostazol treatment was used in the present study.
Mice were perfused intracardially with phosphate
buffer saline, cerebral hemispheres removed and snap
frozen in liquid nitrogen. All experimental proce-
dures were approved by the Institutional Animal Care
and Use Committee at the National Cerebral and
Cardiovascular Center, Japan.
Proteomic analysis
For experiments A and B, respectively, cerebral
hemispheres were suspended in dissolution buffer
(0.5 M triethylammonium bicarbonate, 0.05%
sodium dodecyl sulfate) and homogenized using the
FastPrep system (Savant Bio, Cedex, Fr) followed
by pulsed probe sonication (Misonix, Farmingdale,
NY, USA). Lysates were subjected to centrifugation
(16,000 g, 10 min, 4°C) and supernatants measured
for protein content using the Direct DetectTM system
(Merck Millipore, Darmstadt, Germany). For exper-
iments A and B separately, protein extracts were
pooled from each hemisphere of the three vehicle
treated mice (33.3g from each lysate giving 100g
final protein content). Left and right hemispheres of
cilostazol treated mice were individually analyzed
(100g from each lysate). All samples were sub-
jected to reduction, alkylation, trypsin proteolysis,
eight-plex iTRAQ labeling and two-dimensional
liquid chromatography, tandem mass spectrometry
analysis as described previously [8, 14, 15] (Fig. 1A).
Unprocessed raw files were submitted to Pro-
teome Discoverer 1.4 for target decoy searching
with SequestHT [8, 14]. Quantification ratios were
median-normalized and log2 transformed. After
treatment, a protein was considered differentially
expressed in the left compared to the right hemisphere
relative to its respective control when its two-group
T-Test p-value across both experiments was equal to
or below 0.05.
Principal component analysis (using the iTRAQ
ratios of all analyzed proteins for experiments A and
B) was performed using BioConductor-R (version
2.15.1) and g-plots in R (version 3.1.2). Heatmap con-
struction of differentially expressed proteins between
the two hemispheres was generated using Gene Clus-
ter (version 3.0) and Java Treeview (version 1.1.6r4).
Ingenuity Pathway Analysis (Qiagen, Venlo, Nether-
lands) was applied to identify canonical pathways
and biological processes enriched in the differentially
expressed proteins between right and left cerebral
hemispheres. An |activation z-score|≥ 2.0 and a
p-value≤ 0.05 were considered significant.
RESULTS
A total of 9,116 proteins were quantitatively ana-
lyzed in experiment A (p < 0.05) and another 7,418
proteins in experiment B (p < 0.05), of which 6,137
were reproducibly profiled in both experiments. The
average coefficient variation (CV) for the iTRAQ
ratios of all proteins profiled across biological repli-
cates was determined to be 24% and 23% for the
right and left hemispheres, respectively, of cilostazol
treated mice compared to control in experiment A
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Fig. 1. A) Experimental workflow. B) Principal component analysis for each experiment showed separate clustering for the right and left
hemispheres of cilostazol treated mice compared to controls suggesting hemisphere asymmetry of pharmacologic response to cilostazol
treatment. C) Hierarchical clustering analysis of differentially expressed proteins between the right and left hemispheres in both experiments
visualized in heatmap format. D) Canonical pathway analysis of differentially expressed proteins between right and left hemisphere following
cilostazol treatment showed that the G beta-gamma (G) signaling pathway significantly decreased in the right (p = 1.16E-2; activation
z-score = –2.646) whereas it significantly increased in the left hemisphere of cilostazol treated mice (p = 1.16E-2; activation z-score = 2.646).
and 15% and 16% for the right and left hemispheres,
respectively, of cilostazol treated mice compared
to control in experiment B. Analogous CV values
between biological replicates were reported by the
authors using similar proteomic methodologies [14,
15]. Principal component analysis of the reporter
ion ratios of proteins profiled in each experiment
showed that the right hemispheres clustered sepa-
rately from the left hemispheres of cilostazol treated
mice (Fig. 1B). Following treatment with cilostazol,
765 proteins were differentially expressed between
the right and left cerebral hemispheres across both
proteomic experiments (p≤ 0.05) (Fig. 1C) (Supple-
mentary Table 1).
Bioinformatics interpretation of proteomic
results
Ingenuity Pathway Analysis (IPA) using the aver-
age reporter ion ratios across both experiments
of differentially expressed proteins between right
and left hemisphere following cilostazol treatment
showed that the G beta-gamma (G) signaling path-
way significantly decreased in the right hemisphere
of cilostazol treated mice (p = 1.16E-2; activation
z-score = –2.646) whereas it significantly increased
in the left hemisphere of cilostazol treated mice
(p = 1.16E-2; activation z-score = 2.646) (Fig. 1D).
IPA also showed that aggregation of blood platelets
significantly decreased in the right hemisphere only
of cilostazol treated mice (p = 3.98E-3; activation
z-score = –2.231) (Fig. 2A) whereas neurodegener-
ation significantly decreased (p = 7.7E-6; activation
z-score = –2.071) (Fig. 2B) and synaptic transmis-
sion significantly increased (p = 8.62E-6; activation
z-score = 2.028) (Fig. 2C) specifically in the left
hemisphere of cilostazol treated mice.
DISCUSSION
This study provided novel protein level evidence
on the hemisphere-specific pharmacologic effects of
cilostazol, a drug that has been reported to ame-
liorate the symptoms of Alzheimer’s disease [16].
This observation may have important implications
for an ongoing clinical trial assessing the efficacy of
cilostazol in mild cognitive impairment (COMCID
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Fig. 2. Bioinformatics interpretation of the results showed that (A) aggregation of blood platelets significantly decreased in the right
hemisphere (p = 3.98E-3; activation z-score=–2.231) whereas (B) neurodegeneration significantly decreased (p = 7.7E-6; activation z-
score = –2.071) and (C) synaptic transmission significantly increased (p = 8.62E-6; activation z-score = 2.028) in the left hemisphere of
cilostazol treated mice.
trial, ClinicalTrials.gov identifier: NCT02491268)
but may also be extended to other pharmacologic
agents.
There are only few studies examining cerebral
laterality in the pathophysiology of Alzheimer’s
disease. Douaud et al. [17] suggested that neurode-
generative pathology may develop asymmetrically
in humans, with left hemisphere atrophy being an
important predictor of progression from mild cog-
nitive impairment to Alzheimer’s disease. Singh et
al. [5] have found that atrophy of the cerebral cor-
tex occurred earlier and progressed faster in the left
compared to the right hemisphere in patients with
Alzheimer’s disease. Their findings confirmed pre-
vious observations by Chetelat et al. [18] on left
lateralization of temporal changes occurring during
mild cognitive impairment to Alzheimer’s disease
transition. Thompson et al. [19] examined the dynam-
ics of grey matter loss in Alzheimer’s disease and
concluded that shifting deficits were asymmetric and
predominantly occurring in the left compared to the
right hemisphere.
Our results showed that cilostazol asymmetri-
cally affected the two hemispheres of a transgenic
Alzheimer’s disease mouse model. In the right hemi-
sphere, aggregation of blood platelets was found to
significantly decrease following cilostazol treatment
(Fig. 2A). Cerebral amyloid angiopathy (CAA), char-
acterized by the deposition of amyloid-beta in the
walls of cerebral arteries plays an important role
in the pathogenesis of Alzheimer’s disease. Recent
evidence suggests that platelet activation may also
contribute to the development of CAA [20, 21]. Tar-
geting blood platelets has been examined as a new
venue for the treatment of Alzheimer’s disease and
cilostazol is a well-established antiplatelet agent cur-
rently used for the secondary prevention of cerebral
infarction [22, 23].
In the left hemisphere, cilostazol decreased neu-
rodegeneration (Fig. 2B) and increased synaptic
transmission (Fig. 2C), both suggestive of an
improvement to the neurodegenerative phenotype.
Furthermore, G signaling was asymmetrically
increased in the left and decreased in the right cerebral
hemisphere following cilostazol treatment (Fig. 1D).
G-protein coupled receptors are highly diverse mem-
brane proteins that participate in the transduction
of external signals to various subcellular compart-
ments via trimetric G-proteins. G-protein signaling
in the central nervous system has been implicated
in nuclear gene expression and cytoskeletal reorga-
nization, processes that significantly contribute to
synaptic plasticity and memory [24]. To further inves-
tigate whether these processes were on- or off-target
effects of cilostazol was beyond the scope of the
present proof-of-concept study.
In conclusion, our pharmacoproteomic study
provides novel endophenotypic evidence on the
hemisphere-specific pharmacologic effects of
cilostazol. Future studies should account for hemi-
sphere laterality with important implications in
deciphering regional pharmacodynamic effects of
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existing drugs thus uncovering new hemisphere-
specific therapeutic targets.
Some limitations of the present study include the
non-validated proteomic findings using an alternative
technique (e.g., immunohistochemistry). Further-
more, sub-regions of the cerebral hemispheres (e.g.,
hippocampus, cortex, cerebellum) were not studied
separately to identify regional asymmetric patterns
of pharmacologic response to treatment. These
constitute objectives in future studies.
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